Intepirdine
From Wikipedia, the free encyclopedia
(Redirected from SB-742457)
 |
|
| Clinical data | |
|---|---|
| Routes of administration |
Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
|
|
| Synonyms | SB-742457, RVT-101 |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| ECHA InfoCard | 100.158.094 |
| Chemical and physical data | |
| Formula | C19H19N3O2S |
| Molar mass | 353.44 g/mol |
| 3D model (Jmol) | |
|
|
|
|
  (what is this?) (verify) |
|
Intepirdine (INN; developmental codes SB-742457, RVT-101[1]) is a selective 5-HT6 receptor antagonist with potential cognition, memory, and learning-enhancing effects.[2][3][4][5] It was under development by GlaxoSmithKline for the treatment of Alzheimer's disease and demonstrated some preliminary efficacy in phase II clinical trials;[4][5][6] however, GSK chose not to continue development and sold the rights to Axovant Sciences in December 2014.[7][8]
A phase 3 clinical trial for Alzheimer's is due to report in 2017.[9][10]
It is also in a phase 2 trial for dementia with Lewy bodies.[11]
References[edit]
- ^ "RVT-101". Axovant.
- ^ Upton N, Chuang TT, Hunter AJ, Virley DJ (July 2008). "5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease". Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics. 5 (3): 458–69. doi:10.1016/j.nurt.2008.05.008. PMID 18625457.
- ^ Idris N, Neill J, Grayson B, et al. (January 2010). "Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms". Psychopharmacology. 208 (1): 23–36. doi:10.1007/s00213-009-1702-5. PMID 19851757.
- ^ a b Maher-Edwards G, Zvartau-Hind M, Hunter AJ, et al. (December 2009). "Double-Blind, Controlled Phase II Study of a 5-HT6 Receptor Antagonist, SB-742457, in Alzheimer's Disease". Current Alzheimer Research. 7 (5): 374–85. PMID 20043816.
- ^ a b Rossé G, Schaffhauser H (February 2010). "5-HT(6) Receptor Antagonists as Potential Therapeutics for Cognitive Impairment". Current Topics in Medicinal Chemistry. 10 (2): 207–21. doi:10.2174/156802610790411036. PMID 20166958.
- ^ "Search of: SB-742457 - List Results - ClinicalTrials.gov".
- ^ "Axovant Acquires SB742457 from GlaxoSmithKline" (Press release). Axovant. December 23, 2014.[self-published source]
- ^ House, Douglas W. (June 5, 2015). "Axovant Sciences on deck for IPO". Seeking Alpha.
- ^ NeuroBreak: Alzheimer's Drug Bombs; Sept 2016
- ^ Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study
- ^ Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study
